Skip to main content
. 2025 Feb 8;27(8):3535–3542. doi: 10.1007/s12094-025-03852-x

Table 2.

Comparison of responses between the group with immunotherapy with pembrolizumab versus the group without immunotherapy

All n = 56 “IO Negative group” n = 38 “IO Positive group” p-value n = 18 p < 0.001
RECIST 1.1 n (%)
Complete Response 13 (23.2%) 6 (15.8%) 7 (38.9%)
Partial Response 16 (28.6%) 6 (15.8%) 10 (55.6%)
Stable Disease 11 (19.6%) 11 (28.9%) 0
Progressive Disease 16 (28.6%) 15 (39.5%) 1 (3.6%)